InterMune Inc (ITMN.O)

ITMN.O on Nasdaq

45.50USD
25 Jul 2014
Price Change (% chg)

$-0.43 (-0.94%)
Prev Close
$45.93
Open
$45.93
Day's High
$46.44
Day's Low
$45.29
Volume
934,056
Avg. Vol
2,193,502
52-wk High
$47.72
52-wk Low
$10.95

ITMN.O

Chart for ITMN.O

About

InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone,... (more)

Overall

Beta: 5.32
Market Cap (Mil.): $4,499.18
Shares Outstanding (Mil.): 98.88
Dividend: --
Yield (%): --

Financials

  ITMN.O Industry Sector
P/E (TTM): -- 106.36 36.09
EPS (TTM): -2.66 -- --
ROI: -42.26 -0.18 18.19
ROE: -85.47 -1.06 19.06
Search Stocks

InterMune to resubmit lead drug for US approval after trial success

- InterMune Inc shares jumped as much as 15 percent on Monday, after the biotechnology company said it would resubmit for U.S. approval its drug to treat a fatal lung disease after it was successful in a late-stage study.

19 May 2014

InterMune to resubmit lead drug for US approval after trial success

May 19 - InterMune Inc shares jumped as much as 15 percent on Monday, after the biotechnology company said it would resubmit for U.S. approval its drug to treat a fatal lung disease after it was successful in a late-stage study.

19 May 2014

UPDATE 1-AbbVie drops legal action in EU drug secrecy case

* Decision follows EMA acceptance of redactions to documents

03 Apr 2014

InterMune shares jump as Boehringer's rival drug shows mixed results

BANGALORE - Shares of InterMune Inc rose as much as 17 percent on Friday after data showed German drugmaker Boehringer Ingleheim's rival drug had mixed results in late-stage trials.

21 Mar 2014

InterMune shares jump as Boehringer's rival drug shows mixed results

BANGALORE, March 21 - Shares of InterMune Inc rose as much as 17 percent on Friday after data showed German drugmaker Boehringer Ingleheim's rival drug had mixed results in late-stage trials.

21 Mar 2014

With eye on tax rates, Horizon Pharma buys Ireland's Vidara

- Horizon Pharma Inc said it would buy Dublin-based Vidara Therapeutics International Ltd in a reverse merger for $660 million, the latest U.S. company looking to benefit from Ireland's low corporate tax rates.

19 Mar 2014

Drugmaker InterMune attracts takeover interest: sources

NEW YORK - InterMune Inc , a drugmaker that specializes in treating fatal scarring of the lungs, is attracting takeover interest from several pharmaceutical companies, according to people familiar with the matter.

07 Mar 2014

Drugmaker InterMune attracts takeover interest -sources

NEW YORK, March 7 - InterMune Inc, a drugmaker that specializes in treating fatal scarring of the lungs, is attracting takeover interest from several pharmaceutical companies, according to people familiar with the matter.

07 Mar 2014

InterMune lung drug passes trial, shares nearly triple

- InterMune Inc's lead drug reduced the progression of a fatal lung disease in a late stage trial, inching closer to U.S. approval and almost tripling the company's shares.

25 Feb 2014

UPDATE 2-InterMune lung drug passes trial, shares nearly triple

Feb 25 - InterMune Inc's lead drug reduced the progression of a fatal lung disease in a late stage trial, inching closer to U.S. approval and almost tripling the company's shares.

25 Feb 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $102.11 -0.09
Novartis AG (NOVN.VX) CHF79.95 -0.45
Sanofi SA (SASY.PA) €75.98 -1.34
Gilead Sciences, Inc. (GILD.OQ) $89.84 -0.70
Biogen Idec Inc (BIIB.OQ) $335.45 -1.34
Celgene Corporation (CELG.OQ) $87.16 +0.97
Actelion Ltd (ATLN.VX) CHF110.80 -1.40

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks